No Data
No Data
Capricor Therapeutics' Earnings Call Highlights Progress and Challenges
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $30
Capricor Therapeutics: Promising Developments and Strategic Partnerships Drive Buy Rating
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Piper Sandler Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43